Endocarditis Caused by Nontypeable Streptococcus pneumoniae

The Streptococcus pneumoniae capsule is regarded as indispensable in bacteremia. We report an infant with a ventricular septal defect and infective endocarditis caused by nontypeable S. pneumoniae. In-depth investigation confirmed a deficient capsule yet favored pneumococcal fitness for causing infe...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 75; no. 4; pp. 719 - 722
Main Authors Henriet, Stefanie S V, Langereis, Jeroen D, Lo, Stephanie W, Bentley, Stephen, Mesman, Rob J, Fejzic, Zina, van Niftrik, Laura, van Sorge, Nina M, Wertheim, Heiman F L, de Jonge, Marien I, Cremers, Amelieke J H
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 10.09.2022
Subjects
Brief Report
Endocarditis - diagnosis
Endocarditis, Bacterial - diagnosis
Humans
Infant
Pneumococcal Infections - diagnosis
Pneumonia
Streptococcus pneumoniae
pathogenesis
bacterial polysaccharide capsule
infective endocarditis
Streptococcus pneumoniae
Online AccessGet full text

Cover

More Information
Summary:The Streptococcus pneumoniae capsule is regarded as indispensable in bacteremia. We report an infant with a ventricular septal defect and infective endocarditis caused by nontypeable S. pneumoniae. In-depth investigation confirmed a deficient capsule yet favored pneumococcal fitness for causing infective endocarditis, rather than a host immune disorder, as the cause of infective endocarditis in this case.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Potential conflicts of interest. N. M. v. S. reports that patent WO 2013/020090 A3 has been licensed by the company Vaxcyte, generating royalties when milestones are reached and royalties from a patent on vaccine development against Streptococcus pyogenes, not part of the work submitted here (licensee University of California San Diego inventors, N. M. v. S. and Victor Nizet). N. M. v. S. also reports consulting fees from MSD (fee for service paid directly to the institution, related to pneumococcal invasive disease, and consulting fee for an expert panel) and GlaxoSmithKline (fee for service paid directly to the institution, related to pneumococcal invasive disease); payment or honoraria from MSD for expert meeting contribution on pneumococcal disease); and personal stocks from GenMab, Bank of America, and exchange-traded funds. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciac079